These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28800777)

  • 1. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.
    Ikeda T; Fujii H; Nose M; Kamogawa Y; Shirai T; Shirota Y; Ishii T; Harigae H
    Arthritis Res Ther; 2017 Aug; 19(1):187. PubMed ID: 28800777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
    Jonsson CA; Svensson L; Carlsten H
    Clin Exp Immunol; 1999 Jun; 116(3):534-41. PubMed ID: 10361247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of CD40 siRNA on inflammatory response of MRL/Lpr mice].
    Wang ZH; Zhang W; Zhang YQ; Pang CY; Wang YF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):771-776. PubMed ID: 27752154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
    Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
    Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
    Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
    Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
    Yang J; Li Q; Yang X; Li M
    Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
    Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
    Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
    Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
    Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
    Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
    Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
    Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
    Jimenez-Caliani AJ; Jimenez-Jorge S; Molinero P; Rubio A; Guerrero JM; Osuna C
    J Pineal Res; 2008 Sep; 45(2):204-11. PubMed ID: 18507713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
    Taylor EB; Barati MT; Powell DW; Turbeville HR; Ryan MJ
    Hypertension; 2018 Apr; 71(4):719-728. PubMed ID: 29378858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
    Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
    Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice.
    Woo J; Wright TM; Lemster B; Borochovitz D; Nalesnik MA; Thomson AW
    Clin Exp Immunol; 1995 Apr; 100(1):118-25. PubMed ID: 7535208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
    Hu N; Long H; Zhao M; Yin H; Lu Q
    Scand J Rheumatol; 2009; 38(6):464-71. PubMed ID: 19922023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of lupus dermatoses in autoimmune mice. XIX. Attempts to induce subepidermal immunoglobulin deposition in MRL/Mp- +/+ mice.
    Furukawa F; Ohshio G; Imamura S
    Arch Dermatol Res; 1993; 285(1-2):20-6. PubMed ID: 8470930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.